partnering360 is part of the KNect365 of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
 
World RARE Disease Day shines a light on rare disease community

Tomorrow is the 10th annual World RARE Disease Day. Various activities are taking place all over the United States as well as countless locations around the world.

World RARE Disease Day is an annual observance held on the last day of February to raise awareness for rare diseases, in hopes of improving access to treatments and medical representation for individuals with rare diseases and their families.  Global Genes is one of the leading rare disease patient advocacy organizations worldwide and a consistent supporter of this important day of awareness.  Since 2009, Global Genes and hundreds of patient advocacy organizations around the world have engaged in awareness raising activities developed by Global Genes in support of World Rare Disease Day! (more…)

Share Button
Barcelona biotech companies shine light on regional entrepreneurship

Investors are always on the lookout for innovative biotech startups, and the Catalonia, Spain biopharma cluster has plenty to offer in the way of innovation from among its member companies. Biocat, the incubator for the growth of Catalonia’s BioRegion, comprises 824 companies which have brought over EUR 151 million in investment to Spain between 2013 and 2016. (more…)

Share Button
What’s the deal with Immuno-oncology partnering?

Insight wanted to get the lay of the I/O landscape, so who better to speak with than Jeff Bockman, Vice President of Defined Health. Not only was Jeff kind enough to share his insights with us, but he also had an extensive slide deck on “Immuno-Oncology Partnering: Tipping Point or Tip of the Iceberg?” Below we feature some of his slides along with some of his top line comments.

(more…)

Share Button
Why the connected patient is the killer app in the digital age of medicine

Guest article by Deb Kilpatrick, PhD, CEO at Evidation Health and Rich Milani, MD, FACC, FAHA, Chief Clinical Transformation Officer at Ochsner Health System

If you search on the phrase “killer app,” you will find a definition along the lines of a feature, function, or application of a new technology or product that is presented as virtually indispensable. The two essential components of the killer app being: (more…)

Share Button
Barcelona’s GP Pharm considers partnering key to international expansion

Barcelona is an attractive location for business and trade, and has experienced a revival in the biopharma sector in recent years with the outsourcing of innovation from pharma companies to biotech partners. Insight recently interviewed GP Pharm CEO Dr. Berta Ponsati for insight into their partnering and growth strategy, and why Barcelona companies are ripe for international collaboration.

Insight: GP Pharm is a private Spanish biopharmaceutical firm located in the Barcelona area. The company, founded in 2000, works with companies as a strategic partner to achieve bring science to society by developing products from the laboratory to the market. How would you describe GP Pharm to a potential partner? (more…)

Share Button
Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?

Amid tirelessly pursuing possible partnerships and investment opportunities to bring revolutionary medical products to market at Biotech Showcase™ 2017 in San Francisco, global executives were invited to explore the future of patient care known as digital medicine at a congruent event called Digital Medicine Showcase.

Co-produced by EBD Group and Demy-Colton at the Parc 55 in San Francisco Jan. 10–11, the event was bustling with industry dignitaries ready to explore the future of this emerging new approach to patient care.

The opening panel session, “The State of the Digital Medicine Industry,” facilitated a broad discussion and overview about what digital medicine is, why it is important to patient care, why many in the medical industry dismiss it, and where the future of this segment is going. (more…)

Share Button
Welcome to Barcelona—one of the most vibrant life sciences hubs in Europe

Guest article by BIOCAT, the Bioregion of Catalonia

After the great success of previous editions (2010 and 2013), the Bioregion of Catalonia is again hosting BIO-Europe Spring® 2017 (March 20–22), in the framework of a strong and dynamic life sciences ecosystem.

“Hosting BIO-Europe Spring again is an outstanding opportunity to bring together the international community and offer new partnering opportunities to the most relevant agents,” said Albert Barberà, CEO of Biocat, the organization that coordinates and promotes the health and life sciences sector in Catalonia.

In fact, according to the FDI European Cities and Regions of the Future 2016/2017 report (FDI Intelligence division of the Financial Times), Catalonia will be Southern Europe’s most attractive region for foreign investment. Furthermore, Barcelona is in the lead to be among the top 10 European cities of the future. (more…)

Share Button
UK Establishment upbeat about Brexit’s effect on British life science industry

Brexit may no longer be at the top of popular news, but it continues to be a key concern for biopharma companies in post-Brexit 2017. The sentiment of key players from the UK life sciences from a panel at #BiotechShowcase 2017 in San Francisco this week was overwhelmingly positive. Overall, the Brexit definitely means change for the industry and future collaboration opportunities, but change can be a good thing.

There are four key issues for consideration relevant to the threats and opportunities presented by Brexit, according to Steve Bates, CEO, UK BioIndustry Association: (more…)

Share Button
Taming the Wild West of digital medicine

The new paradigm of healthcare is widely becoming known as “The Digital Health Revolution,” referring to medical technology advancements so great that when combined with wearables, medication sensors and amplified data analysis, they can provide patients and physicians with greater power to measure and improve treatment outcomes.

But what does it mean to the current state and future of the healthcare industry? It’s our industry’s modern-day conundrum and much like the advancement of cell phones, the technology isn’t going away and adaptation is inevitable over time. (more…)

Share Button
Investors’ appetite for the life sciences continued in 2016

Guest post by Doro Shin, Thought Leadership Manager at Informa Pharma Intelligence

While 2015 was a record year for investments within the life sciences industry, investors became wary toward the end of the year and activities declined in the fourth quarter. Although enthusiasm appeared to wane, the downward trend didn’t carry over to 2016 according to an upcoming white paper, Finding Finance: Pharma, Biotech & Medtech Capital Raising 2016. Drawing on Informa’s Pharma Intelligence data assets Medtrack and Strategic Transactions, the analysis found that capital continued to flow into the life sciences sector and the industry remained an attractive place for investors in 2016. (more…)

Share Button